• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

    4/21/25 8:00:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NXL alert in real time by email

    HOUSTON, TX, April 21, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced its support for the Health Tech Investment Act (S. 1399) — bipartisan legislation introduced in the United States Senate that would expand Medicare reimbursement opportunities for FDA-cleared or approved medical devices that incorporate artificial intelligence (AI) or machine learning.

    The legislation, sponsored by Senators Mike Rounds (R-S.D.) and Martin Heinrich (D-N.M.), proposes a transitional reimbursement mechanism under Medicare to close the current gap between device approval and coverage. Under the proposal, AI-enabled technologies that receive FDA clearance or approval would be assigned New Technology Ambulatory Payment Classification (APC) codes for up to five years, allowing time for the Centers for Medicare & Medicaid Services (CMS) to collect clinical data and assess long-term reimbursement decisions.

    Nexalin's upcoming Gen-3 HALO Clarity™ device, currently under development for FDA submission, is a next-generation neurostimulation system that integrates advanced AI capabilities into both treatment delivery and patient monitoring. The device is designed to deliver non-invasive, low-frequency waveforms that target key brain regions associated with anxiety, depression, insomnia, and related mental health conditions. In tandem with the device itself, Nexalin has built a proprietary virtual clinic ecosystem that utilizes artificial intelligence to support remote treatment, real-time clinical feedback, and secure data capture — all through an integrated Electronic Data Capture (EDC) platform and Patient Monitoring System (PMS).

    The Company recently completed Phase 1 of its AI-powered virtual clinic infrastructure, which enables patients to initiate therapy at home via a secure mobile app, while clinicians and researchers receive automated, real-time insights through AI-enabled dashboards. This ecosystem is engineered specifically to support the Gen-3 HALO Clarity™ device and is a core component of Nexalin's strategy to enhance mental health care through technology-driven solutions.

    "The Health Tech Investment Act reflects a shift in national health policy toward supporting intelligent, patient-centered innovations," said Mark White, CEO of Nexalin. "Our Gen-3 HALO Clarity™ device exemplifies that approach — combining precision neurostimulation with AI-driven tools that improve care coordination, monitoring, and adherence. This legislation provides a reimbursement path that recognizes and supports this model of care."

    The Gen-3 HALO Clarity™ device has been designed to meet the needs of both patients and providers in an increasingly digital healthcare environment. It expands upon the clinical foundation laid by Nexalin's earlier-generation systems, adding intelligent features that allow clinicians to personalize treatment, analyze real-time outcomes, and ensure protocol compliance — whether in the clinic or remotely. The Company is currently preparing for FDA submission of the Gen-3 device following planned clinical trials.

    Nexalin views the Health Tech Investment Act as a legislative milestone that could provide a reimbursement framework ideally suited to the Gen-3 HALO Clarity™ device. The bill offers a clear signal that federal policymakers are prioritizing the intersection of innovation and accessibility, especially in areas like mental health, where traditional care options remain limited or ineffective for many patients.

    As the bill advances through Congress, Nexalin remains focused on its regulatory and clinical milestones and supports swift bipartisan action to bring this important legislation into law.

    About Nexalin Technology, Inc.

    Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.

    Forward-looking statements

    This press release contains statements that constitute "forward-looking statements," These statements relate to future events or Nexalin's future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management "believes", "expects", "anticipates", "plans", "intends" and similar expressions) should be considered forward-looking statements that involve risks and uncertainties which could cause actual events or Nexalin's actual results to differ materially from those indicated by the forward-looking statements.  Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023, and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

    Contact:

    Crescendo Communications, LLC

    Tel: (212) 671-1020

    Email: [email protected] 





    Primary Logo

    Get the next $NXL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NXL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NXL
    Leadership Updates

    Live Leadership Updates

    See more
    • Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data

      HOUSTON, TX, May 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the reconstitution of its Scientific Advisory Board (SAB) with the appointment of three renowned experts in neurology, neuroimaging, and neurodegenerative diseases. This move reflects Nexalin's strategic prioritization of Alzheimer's disease within its broader clinical development pipeline, supported by promising published data and internal data from studies involving its proprietary DIFS™ technology. Joining the SAB are Dr. Mingxiong Huang, Dr. David Owens, and Dr. Abe Scheer, e

      5/13/25 8:30:00 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

      HOUSTON, TX, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is honored to announce that General Wesley K. Clark (Ret.), former NATO Supreme Allied Commander Europe, has joined its Military & Government Advisory Board. General Clark will collaborate with esteemed members David F. Lasseter, former Deputy Assistant Secretary of Defense for Policy, and William A. Hudson, Jr., former Acting General Counsel to the Department of Veterans Affairs, to advance Nexalin's innovative neurostimulation solutions within U.S. military and government sectors. The Company'

      2/26/25 8:30:00 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

      HOUSTON, TX, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW))) (the "Company" or "Nexalin") announces the appointment of Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs. With more than 30 years of experience in the medical device industry, Shelton brings a wealth of knowledge in regulatory compliance, quality assurance, and clinical development. In her role, she will oversee all clinical studies, quality systems, and regulatory submissions, ensuring Nexalin's commitment to innovation, safety, and excellence as the Company prepares to pursue global regulatory clearances and future FDA Breakthrough Device designations for its

      10/14/24 8:30:00 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NXL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sr. VP - Quality, Regulatory Shelton Carolyn Hamby bought $13,200 worth of shares (6,000 units at $2.20) (SEC Form 4)

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      3/13/25 4:52:26 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Medical Officer Owens David bought $3,100 worth of shares (1,000 units at $3.10), increasing direct ownership by 0.65% to 155,793 units (SEC Form 4)

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      2/5/25 3:17:26 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Medical Officer Owens David bought $2,980 worth of shares (1,000 units at $2.98), increasing direct ownership by 0.65% to 154,793 units (SEC Form 4)

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      2/4/25 5:05:25 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NXL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sr. VP - Quality, Regulatory Shelton Carolyn Hamby bought $13,200 worth of shares (6,000 units at $2.20) (SEC Form 4)

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      3/13/25 4:52:26 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by President and CEO White Mark

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      2/27/25 4:34:13 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Owens David

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      2/27/25 4:33:38 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NXL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3

      HOUSTON, TX, May 28, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW)) is pleased to invite investors to a webinar on June 3, 2025, at 4:15 p.m. ET. Attendees will gain an inside look at Nexalin's game-changing approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology. CEO Mark White will detail the Company's growing body of clinical evidence, including collaborations with leading institutions like UC San Diego, and share updates on the Gen-3 HALO™ Clarity headset and Virtual Clinic model—designed for scalable, at-home treatment. With regulatory approvals secured interna

      5/28/25 10:00:00 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data

      HOUSTON, TX, May 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the reconstitution of its Scientific Advisory Board (SAB) with the appointment of three renowned experts in neurology, neuroimaging, and neurodegenerative diseases. This move reflects Nexalin's strategic prioritization of Alzheimer's disease within its broader clinical development pipeline, supported by promising published data and internal data from studies involving its proprietary DIFS™ technology. Joining the SAB are Dr. Mingxiong Huang, Dr. David Owens, and Dr. Abe Scheer, e

      5/13/25 8:30:00 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering

      HOUSTON, May 06, 2025 (GLOBE NEWSWIRE) --  Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the closing of its previously announced underwritten public offering of 3,850,000 shares of its common stock at a public offering price of $1.30 per share. The gross proceeds from the offering to Nexalin were approximately $5.0 million, before deducting underwriting discounts and commissions and other offering expenses. Maxim Group LLC acted as sole book-running manager for the offering. The public offering was made pursuant to an effective shelf registration statement on Form S-3

      5/6/25 2:40:23 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NXL
    Financials

    Live finance-specific insights

    See more
    • LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / November 1, 2024 / RedChip Companies will air interviews with LOBO EV Technologies Ltd. (NASDAQ:LOBO) and Nexalin Technology, Inc. (NASDAQ:NXL) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:LOBO EV: https://www.redchip.com/assets/access/lobo_accessNexalin: https://www.redchip.com/assets/access/nxl_accessIn an exclusive interview, Harry D. Schulman, Independent Director of LOBO EV Technologies, appears on the RedChip Small Stocks Big Money™ show on Bloomberg T

      11/1/24 9:00:00 AM ET
      $LOBO
      $NXL
      Motor Vehicles
      Consumer Discretionary
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (NASDAQ:NXL) and Calidi Biotherapeutics, Inc. (NYSE:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 26, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nexalin: https://www.redchip.com/assets/access/nxl_accessCalidi: https://www.redchip.com/assets/access/cldi_accessIn an exclusive interview, Mark White, CEO of Nexalin Technology, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate

      10/25/24 9:00:00 AM ET
      $CLDI
      $NXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / July 26, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (NASDAQ:NXL) and LOBO EV Technologies Ltd. (NASDAQ:LOBO) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 27, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nexalin: https://www.redchip.com/assets/access/nxl_accessLOBO EV: https://www.redchip.com/assets/access/lobo_accessMark White, CEO of Nexalin, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. Nexalin stands at the forefront of th

      7/26/24 9:55:00 AM ET
      $LOBO
      $NXL
      Motor Vehicles
      Consumer Discretionary
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NXL
    SEC Filings

    See more
    • SEC Form 10-Q filed by Nexalin Technology Inc.

      10-Q - Nexalin Technology, Inc. (0001527352) (Filer)

      5/13/25 3:31:04 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nexalin Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - Nexalin Technology, Inc. (0001527352) (Filer)

      5/6/25 12:39:21 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 424B4 filed by Nexalin Technology Inc.

      424B4 - Nexalin Technology, Inc. (0001527352) (Filer)

      5/6/25 11:44:26 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care